DDC Enterprise Announces First Half 2025 Earnings Conference Call for September 4, 2025

DDC Enterprise Limited (NYSE: DDC) ("DDC" or the " Company "), an Asian consumer-first company at the forefront of corporate bitcoin acquisition and treasury management, today announced it will report its financial results for the first half of 2025 on Thursday, September 4, 2025 at 8:00 AM EDT. DDC will cover the financial results for the six months ended June 30, 2025, as well as provide a business update.

DDC will release its earnings before the call at approximately 7:00 AM EDT on September 4, 2025. A copy of the earnings release will be available on the Company's Investor Relations website at ir.DDC.xyz.

Conference Call Information:

  • Date : September 4, 2025
  • Time : 8:00 AM EDT
  • Participant Call Links :

Participants wishing to join the conference call by phone should register using the Participant Call Registration link provided above. After completing the registration, the participants will receive an email with the necessary details to access the call, including the dial-in number, passcode, and PIN. To ensure a timely start, the Company encourages all callers to connect 5 minutes before the scheduled time.

A live and archived webcast of the conference call will be available on the Investors section of DDC's website at ir.DDC.xyz.

About DDC Enterprise Limited (NYSE: DDC)

DDC Enterprise Limited (NYSE: DDC) is spearheading the corporate Bitcoin treasury revolution while maintaining its foundation as a leading global Asian food platform. The Company has strategically positioned Bitcoin as a core reserve asset, executing a bold and accelerating accumulation strategy. While continuing to grow its portfolio of culinary brands, DDC is now at the vanguard of public companies integrating Bitcoin into their financial architecture.

Media & Investor Contacts

Investor Relations
Orange Group | Yujia Zhai
ddc@orangegroupadvisors.com

Press and Media
pr@ddc.xyz

News Provided by Business Wire via QuoteMedia

DDC
The Conversation (0)
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors

NUV-1511 is the first clinical candidate from the company's novel drug-drug conjugate platform Company anticipates initiating a Phase 1/2 clinical study of NUV-1511 in 1H 2024 Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by... Keep Reading...
Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Phase 1 monotherapy study of NUV-868 and Phase 1b study of NUV-868 in combination with olaparib or enzalutamide are ongoing Expect to submit an IND for first Drug-Drug Conjugate (DDC) clinical candidate by year end 2023 Strong balance sheet with cash, cash equivalents, and marketable securities... Keep Reading...
Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Enrollment ongoing in the Phase 1b study of NUV-868 in combination with olaparib or enzalutamide Enrollment ongoing in the Phase 1 monotherapy study of NUV-868 Expect to submit an IND for first Drug-Drug Conjugate (DDC) clinical candidate by year end 2023 Announced formation of oncology-focused... Keep Reading...
Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board

Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board

Scientific Advisory Board members bring significant global expertise in oncology drug and clinical development Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today... Keep Reading...
Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update

Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update

Enrollment ongoing in the Phase 1b study of NUV-868 in combination with olaparib or enzalutamide Enrollment ongoing in the Phase 1 monotherapy study of NUV-868 Expect to submit an IND for first Drug-Drug Conjugate (DDC) clinical candidate by year end 2023 Strong balance sheet with cash, cash... Keep Reading...

Charles Schwab's Money Talk Personal Finance Column Expands Bench of Expert Voices

Three new Certified Financial Planners ® join the column's roster of experts creating real-life financial education insight Charles Schwab today announced the addition of three new Certified Financial Planners® to Money Talk, Schwab's personal finance column designed to help everyday Americans... Keep Reading...

Climate Global and Moody's Power the First Index and ETF of Climate-Resilient REITs

Climate Global and Exchange Traded Concepts announced the Climate Global Climate-Resilient REIT Index ETF (Ticker: CLIM), an exchange-traded fund designed to provide exposure to U.S. equity Real Estate Investment Trusts (REITs) while systematically incorporating insurance-grade climate and... Keep Reading...

T. ROWE PRICE OHA SELECT PRIVATE CREDIT FUND ANNOUNCES DECEMBER 31, 2025 FINANCIAL RESULTS AND DECLARED TOTAL DISTRIBUTIONS OF $0.69 PER SHARE IN Q4 2025

T. Rowe Price OHA Select Private Credit Fund (the "Company" or "OCREDIT") today reported financial results and total distributions of $0.69 per share for the quarter ended December 31, 2025. As private credit remains a key driver of financing solutions within credit markets, OCREDIT closed the... Keep Reading...
AmeriTrust Provides Corporate Update

AmeriTrust Provides Corporate Update

TORONTO, ON / ACCESS Newswire / March 11, 2026 / AmeriTrust Financial Technologies Inc. (TSXV:AMT,OTC:AMTFF)(OTCQB:AMTFF)(Frankfurt:1ZVA) ("AmeriTrust", "AMT" or the "Company"), a fintech platform targeting automotive finance is pleased to provide an update of corporate activities since the... Keep Reading...

Interactive Chart

Latest Press Releases

Related News